Arkolith/Insider Trading/CRBP/Form 4

Altmeyer Anne

DirectorCorbus Pharmaceuticals Holdings, Inc. (CRBP) · full profile →Form 4 · filed Oct 21, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$22K
Net Open-Market Flow
-$22K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 20, 2025Option exercise(M)1K$4.80$5K7K
Oct 20, 2025Sell(S)1K$20.50$22K6K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 20, 2025Option exercise(M)1K—$04K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-245262) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML